First Drug to Target "Undruggable" KRAS Cancer Mutation Gets FDA Fast Track Zoldonrasib breakthrough opens new front against aggressive lung cancers The FDA has awarded breakthrough therapy designation to zoldonrasib, representing a historic milestone in cancer treatment as the first investigational drug specifically designed to target the KRAS